Skip to main content

A Medicament to Suppress the Expression of Mutated Kras and Mutated P53 in Colorectal Cancer Cell

Potential Commercialised fa-solid fa-cart-arrow-down violet
Reg. ID : 17051
Comments

Huraian

The present invention discloses anthraquinone compound according to Formula (1) or its pharmaceutical acceptable salts, prodrug and solvates thereof for use in suppressing the expression of mutated KRAS and mutated p53 genes in colorectal cancer cell. In a specific embodiment, the anthraquinone compound according to Formula (1) is also generally named with the chemical compund name of morindone. The anthraquinone compound according to Formula (1) is able to suppress the expression of mutated KRAS and mutated p53 genes of the colorectal cancer cell to prevent the colorectal cancer cells therapies resistance and poor prognosis.

Contact Person/Inventor

Name Email Contact Phone
Um Centre Of Innovation And Enterprise (Umcie) umcie@um.edu.my 013-2250151 / 03-79677351

Intellectual Property

Type of IP Registration ID
1 Patent Granted MY153442A

Award

Award Title Award Achievement Award Year Received
0 0 0

Komen

LOG IN or REGISTER to post comments.

Star Rating

Star Rating
Masih tiada undi

Contact Form